Paclitaxel liposomal - Luye Pharma Group

Drug Profile

Paclitaxel liposomal - Luye Pharma Group

Alternative Names: Liposomal paclitaxel - Luye Pharma Group; Lipusu; Paclitaxel Liposome for Injection

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Luye Pharma Group
  • Developer Luye Pharma Group; Nanjing Sike Pharmaceutical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 04 Oct 2016 No recent reports on development identified - Phase-II for Breast cancer (Combination therapy, Neoadjuvant therapy) in China (IV)
  • 26 Aug 2014 Phase-II clinical trials in Breast cancer (Combination therapy, Neoadjuvant therapy) in China (IV)
  • 19 May 2014 Nanjing Luye Sike Pharmaceutical plans a clinical trial in Breast cancer (neoadjuvant combination therapy) in China (NCT02142010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top